Proton Pump

Related Products

Proton pump is an integral membrane protein that is capable of moving protons across a biological membrane. Mechanisms are based on conformational changes of the protein structure or on theQ cycle. In cell respiration, the proton pump uses energy to transport protons from the matrix of the mitochondrion to the inter-membrane space. It is an active pump, that generates a protonconcentration gradient across the inner mitochondrial membrane, because there are more protons outside the matrix than inside. The difference in pH and electric charge (ignoring differences inbuffer capacity) creates an electrochemical potential difference that works similar to that of a battery or energy storing unit for the cell. The process could also be seen as analogous to cycling uphill or charging a battery for later use, as it produces potential energy. The proton pump does not create energy, but forms a gradient that stores energy for later use.

Proton Pump Related Products (177)
Antibodies (1)

By Effects:	Inhibitors (153) Agonists (3) Controls (3) Antagonists (3) Activator (1)

Cat. No.	Product Name	Effect	Purity	Chemical Structure

HY-146074

RUVBL1/2 ATPase-IN-1	Inhibitor	99.63%
RUVBL1/2 ATPase-IN-1 (compound 18) is a potent and selective inhibitor of RUVBL1/2 ATPase with IC₅₀ values of 6.0 and 7.7 μM, respectively. RUVBL1 and RUVBL2 are highly conserved AAA ATPases (ATPases Associated with various cellular Activities) and highly relevant to the progression of cancer. RUVBL1/2 ATPase-IN-1 has the potential for the research of cancer diseases.

HY-117025A

Manzamine A hydrochloride	Inhibitor	99.66%
Manzamine A hydrochloride, an orally active beta-carboline alkaloid, inhibits specifically GSK-3β and CDK-5 with IC₅₀s of 10.2 μM and 1.5 μM, respectively. Manzamine A hydrochloride targets vacuolar ATPases and inhibits autophagy in pancreatic cancer cells. Manzamine A hydrochloride has antimalarial and anticancer activities. Manzamine A hydrochloride also shows potent activity against HSV-1.

HY-100560S

Abscisic acid-d₆	Inhibitor	99.14%
Abscisic acid-d₆ is deuterium labeled Abscisic acid. Abscisic acid inhibits proton pump (H⁺-ATPase).

HY-103261

SCH28080	Inhibitor	99.0%
SCH28080 is a reversible, K⁺-competitive inhibitor of the gastric H,K-ATPase, with a K_i of 0.12 μM. SCH28080 is an effective inhibitor of acid secretion in vivo and with anti-gastric ulcer activity.

HY-B0113R

Omeprazole (Standard)	Inhibitor
Omeprazole (Standard) is the analytical standard of Omeprazole. This product is intended for research and analytical applications. Omeprazole (H 16868) is an orally active H⁺,K⁺-ATPase inhibitor and a proton pump inhibitor. Omeprazole competitively inhibits CYP2C19, CYP3A4, and CYP2C9 activity. Omeprazole inhibits gastric acid secretion and can be used for acid-related gastrointestinal disorders. Omeprazole inhibits pancreatic cancer cell proliferation, induces apoptosis, autophagosome accumulation (elevated LC3-I and LC3-II levels), oxidative stress, and cytogenetic imbalance, modulates lysosomal transport, reduces inflammatory cytokines. Omeprazole alters small intestinal morphology and magnesium absorption, and induces gastric mucosa morphologic changes. Omeprazole aslo has neuroprotective and antibacterial effects.

HY-B2145A

Ilaprazole sodium hydrate	Inhibitor	99.15%
Ilaprazole (IY-81149) sodium hydrate is an orally active proton pump inhibitor. Ilaprazole sodium hydrate irreversibly inhibits H⁺/K⁺-ATPase in a dose-dependent manner with an IC₅₀ of 6 μM in rabbit parietal cell preparation. Ilaprazole sodium hydrate is used for the research of gastric ulcers. Ilaprazole sodium hydrate is also a potent TOPK (T-lymphokine-activated killer cell-originated protein kinase) inhibitor.

HY-A0213A

Tiludronate disodium	Inhibitor	99.97%
Tiludronate (Tiludronic Acid) disodium, an orally active bisphosphonate, can act an osteoregulator. Tiludronate is used for the research of the metabolic bone disorders. Tiludronate is a potent inhibitor of the osteoclast vacuolar H(+)-ATPase. Antiresorptive and anti-inflammatory properties.

HY-17507B

Pantoprazole sodium hydrate	Inhibitor	99.93%
Pantoprazole sodium hydrate (BY10232 sodium hydrate) is an orally active and potent proton pump inhibitor (PPI). Pantoprazole sodium hydrate, a substituted benzimidazole, is a potent H⁺/K⁺-ATPase inhibitor with an IC₅₀ of 6.8 μM. Pantoprazole sodium hydrate improves pH stability and has anti-secretory, anti-ulcer activities. Pantoprazole sodium hydrate significantly increased tumor growth delay combined with Doxorubicin (HY-15142).

HY-118283

5-Hydroxylansoprazole	Inhibitor	99.75%
5-Hydroxylansoprazole (AG1908) is an active metabolite of Lansoprazole in plasma. Lansoprazole is metabolized by CYP2C19 forming 5-Hydroxylansoprazole. Lansoprazole is a gastric proton-pump inhibitor and is effective in the treatment of various peptic diseases.

HY-400540

Padoprazanum	Inhibitor	98.88%
Padoprazanum (Padoprazan) is a Proton Pump inhibitor.

HY-108970

Bafilomycin D	Inhibitor	99.30%
Bafilomycin D is a specific inhibitor of vacuolar-type ATPase (V-ATPase). Bafilomycin D has antimicrobial, insecticidal, herbicidal and cytotoxic activity.

HY-162935

V-ATPase-IN-1	Inhibitor	99.23%
V-ATPase-IN-1 (Compound 3b-03) is a Vacuolar-type H⁺-ATPases (V-ATPase) inhibitor (IC₅₀ = 194.80 μM) that can effectively target the V-ATPase subunit A (K_d = 0.803 μM). V-ATPase-IN-1 exhibits insecticidal activity against M. separata (LC₅₀ = 2.64 mM) and contributes to research in the development of chemical insecticides.

HY-100412

Linaprazan	Inhibitor	98.80%
Linaprazan (AZD0865) can inhibit H+,K+ -ATPase in the stomach through K+ competitive binding, (IC₅₀: 1.0 ± 0.2 μM), it has a strong inhibitory effect on acid. Linaprazan (AZD0865) can be used for research on reflux esophagitis with oral activity.

HY-W317853

Protonstatin-1	Inhibitor	98.47%
Protonstatin-1 is a selective plasma membrane (PM) H⁺-ATPase inhibitor (IC₅₀ of 3.9 μM) that inhibits auxin transport. Protonstatin-1 interacts with the PM H⁺-ATPase central loop and may thus impede the functions of the N- and/or P-domain to inhibit the pump activity.

HY-13662C

(S)-Lansoprazole	Inhibitor	98.90%
(S)-Lansoprazole (Levolansoprazole) is an isoform of Lansoprazole (HY-13662), which is an orally active proton pump inhibitor which prevents the stomach from producing acid. Lansoprazole (AG 1749) is a potent brain penetrant neutral sphingomyelinase (N-SMase) inhibitor (exosome inhibitor).

HY-N6738

Bafilomycin B1		98.10%
Bafilomycin B1 is a macrolide antibiotic that can be isolated from mycelium of Streptomyces gresuis. Bafilomycin B1 is neuroprotective against Chloroquine (HY-17589A)-induced death. Bafilomycin B1 is a structural analog of Bafilomycin A1 and has the ability to inhibit V-ATPase. Bafilomycin B1 inhibits significantly the oxidized low density lipoprotein (LDL)-induced accumulation of lipid droplets.

HY-B0113S

Omeprazole-d₃	Inhibitor	98.99%
Omeprazole-d₃ (H 16868-d₃) is deuterium labeled Omeprazole. Omeprazole (H 16868) is an orally active H⁺,K⁺-ATPase inhibitor and a proton pump inhibitor. Omeprazole competitively inhibits CYP2C19, CYP3A4, and CYP2C9 activity. Omeprazole inhibits gastric acid secretion and can be used for acid-related gastrointestinal disorders. Omeprazole inhibits pancreatic cancer cell proliferation, induces apoptosis, autophagosome accumulation (elevated LC3-I and LC3-II levels), oxidative stress, and cytogenetic imbalance, modulates lysosomal transport, reduces inflammatory cytokines. Omeprazole alters small intestinal morphology and magnesium absorption, and induces gastric mucosa morphologic changes. Omeprazole aslo has neuroprotective and antibacterial effects.

HY-B0113S3

Omeprazole-¹³C,d₃	Inhibitor	98.00%
Omeprazole-¹³C,d₃ is a ¹³C-labeled and deuterium labeled Omeprazole. Omeprazole (H 16868) is an orally active H⁺,K⁺-ATPase inhibitor and a proton pump inhibitor. Omeprazole competitively inhibits CYP2C19, CYP3A4, and CYP2C9 activity. Omeprazole inhibits gastric acid secretion and can be used for acid-related gastrointestinal disorders. Omeprazole inhibits pancreatic cancer cell proliferation, induces apoptosis, autophagosome accumulation (elevated LC3-I and LC3-II levels), oxidative stress, and cytogenetic imbalance, modulates lysosomal transport, reduces inflammatory cytokines. Omeprazole alters small intestinal morphology and magnesium absorption, and induces gastric mucosa morphologic changes. Omeprazole aslo has neuroprotective and antibacterial effects.

HY-13100

PF 03716556	Antagonist	99.10%
PF 03716556 is a potent, selective, competitive and reversible acid pump (H⁺,K⁺-ATPase) antagonist with pIC₅₀s of 6.026, 6.038 and 6.009 for porcine, canine, and human recombinant gastric H⁺,K⁺-ATPase, respectively. PF 03716556 is inactive against other receptors, ion channels, and enzymes. PF 03716556 has the potential for gastroesophageal reflux disease research.

HY-17021B

Esomeprazole potassium salt	Inhibitor	98.98%
Esomeprazole potassium salt ((S)-Omeprazole potassium salt) is a potent and orally active proton pump inhibitor and reduces acid secretion through inhibition of the H⁺, K⁺-ATPase in gastric parietal cells. Esomeprazole potassium salt has the potential for symptomatic gastroesophageal reflux disease research.

Name
Email *

	Sorry, but the email address you supplied was invalid.

Proton Pump

Proton Pump

Proton Pump Related Products (177)

Antibodies (1)

Proton Pump Related Products (177):